TURKISH JOURNAL OF ONCOLOGY 2024 , Vol 39 , Num 3
Helical IMRT Experience in Adult Medulloblastoma Radiotherapy
Ali Kerim AKSAKAL1,Binnur TUNCER1,Gonca ALTINIŞIK İNAN1,İpek Pınar ARAL1,Zerrin GANİ1,Yılmaz TEZCAN1
1Department of Radiation Oncology, Ankara Bilkent City Hospital, Ankara-Türkiye
2Department of Radiation Oncology, Ankara Yıldırım Beyazıt University, Ankara-Türkiye
DOI : 10.5505/tjo.2024.4264 OBJECTIVE
This study aimed to report the characteristics and treatment results of radiotherapy applied with the helical IMRT technique in the adult medulloblastoma patient group.

METHODS
In this study, adult medulloblastoma patients who received radiotherapy with the Helical Tomotherapy technique in the Ankara City Hospital Radiation Oncology Clinic between March 2019 and October 2022 were analyzed retrospectively. Primary endpoints are reporting of patients" survival and toxicity results.

RESULTS
The analysis was performed on 15 patients. The median follow-up time of the study was 9.4 (1.2?34.7). The median OS is 11.8 (3.9?37.26). The median PFS was 8.5 (1.28?34.73) months. A correlation close to the limit of significance was found between the risk group and PFS (p=0.051). Changes were recorded in the blood values of the patients before the treatment and before the boost treatment. It was determined that the white blood cell (p=0.001) and lymphocyte counts (p=0,001) decreased significantly before the boost treatment. The relationship of these values with lymphocyte count before boost treatment could not be shown statistically.

CONCLUSION
Radiotherapy with HT technique of adult MBL cases, which we rarely encounter in the clinic, has reversible and acceptable acute toxicity rates. Keywords : Adult; helical IMRT; medulloblastoma; radiotherapy